Search Within

Alan Loh Ho

  1. "Biostatistics Service"
Formats
  1. Journal Article (26)
  2. Meeting Abstract (22)
  3. Editorial (1)
  4. Research Letter (1)
Groups
  1. Biostatistics Service (50)
  2. Department of Medicine (50)
  3. Epidemiology and Biostatistics (50)
  4. Head and Neck Service (50)
  5. Solid Tumor Oncology Division (50)
  6. Department of Pathology and Laboratory Medicine (35)

More Groups

People
  1. David Pfister (28)
  2. Eric Sherman (27)
  3. Lara Dunn (19)
  4. Sofia Haque (18)
  5. Nora Katabi (16)
  6. James Fagin (14)

More People

Years
  1. 2024 (7)
  2. 2023 (7)
  3. 2022 (3)
  4. 2021 (4)
  5. 2020 (4)
  6. 2019 (6)

More Years

Publications
  1. Journal of Clinical Oncology (19)
  2. Annals of Oncology (5)
  3. International Journal of Radiation Oncology, Biology, Physics (4)
  4. Clinical Cancer Research (3)
  5. European Journal of Nuclear Medicine and Molecular Imaging (3)
  6. Cancer Chemotherapy and Pharmacology (1)

More Publications

Publishers
  1. American Society of Clinical Oncology (19)
  2. Oxford University Press (7)
  3. Springer (6)
  4. Elsevier Inc. (5)
  5. American Association for Cancer Research (4)
  6. John Wiley & Sons (2)

More Publishers

Results (50)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Tumor mutational load predicts survival after immunotherapy across multiple cancer types
    Research Letter

    Samstein, R. M.; Lee, C. H.; Shoushtari, A. N.; Hellmann, M. D.; Shen, R.; Janjigian, Y. Y.; Barron, D. A.; Zehir, A.; Jordan, E. J.; Omuro, A.; more...
    Nature Genetics (2019)

    Fulltext@MSK | Save
  • A phase II study of lenvatinib in patients with progressive, recurrent/metastatic adenoid cystic carcinoma
    Meeting Abstract

    Tchekmedyian, V.; Sherman, E. J.; Dunn, L.; Tran, C.; Katabi, N.; Ni, A.; Haque, S.; Pfister, D. G.; Ho, A. L.
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • A multi-histology basket trial of ado-trastuzumab emtansine in patients with HER2 amplified cancers
    Meeting Abstract

    Li, B. T.; Makker, V.; Buonocore, D. J.; Offin, M. D.; Olah, Z. T.; Panora, E.; Shen, R.; Ho, A. L.; Yaeger, R.; Iyer, G.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • A phase II randomized trial of nivolumab with stereotactic body radiotherapy (SBRT) versus nivolumab alone in metastatic (M1) head and neck squamous cell carcinoma (HNSCC)
    Meeting Abstract

    McBride, S. M.; Sherman, E. J.; Tsai, C. J.; Baxi, S. S.; Aghalar, J.; Eng, J.; Zhi, W. I.; McFarland, D. C.; Michel, L. S.; Spielsinger, D.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • A phase 1b dose expansion study of the pan-class I PI3K inhibitor buparlisib (BKM120) plus carboplatin and paclitaxel in PTEN deficient tumors and with dose intensified carboplatin and paclitaxel
    Journal Article

    Smyth, L. M.; Monson, K. R.; Jhaveri, K.; Drilon, A.; Li, B. T.; Abida, W.; Iyer, G.; Gerecitano, J. F.; Gounder, M.; Harding, J. J.; more...
    Investigational New Drugs (2017)

    Fulltext@MSK | Save
  • The PARP inhibitor veliparib can be safely added to bendamustine and rituximab and has preliminary evidence of activity in B-cell lymphoma
    Journal Article

    Soumerai, J. D.; Zelenetz, A. D.; Moskowitz, C. H.; Palomba, M. L.; Hamlin, P. A. Jr; Noy, A.; Straus, D. J.; Moskowitz, A. J.; Younes, A.; Matasar, M. J.; more...
    Clinical Cancer Research (2017)

    Fulltext@MSK | Save
  • Phase II study of regorafenib in progressive, recurrent/metastatic adenoid cystic carcinoma
    Meeting Abstract

    Ho, A. L.; Sherman, E. J.; Baxi, S. S.; Haque, S.; Ni, A.; Antonescu, C. R.; Katabi, N.; Morris, L. G.; Chan, T. A. T.; Pfister, D. G.
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Enhancing radioiodine (RAI) incorporation into BRAF(V600E)-mutant, RAI-refractory thyroid cancers with the BRAF inhibitor vemurafenib: A pilot study
    Meeting Abstract

    Dunn, L.; Sherman, E. J.; Baxi, S. S.; Grewal, R. K.; Pentlow, K. S.; Haque, S.; Tuttle, R. M.; Sabra, M.; Fish, S.; Boucai, L.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • A phase II study of axitinib (AG-013736) in patients with incurable adenoid cystic carcinoma
    Journal Article

    Ho, A. L.; Dunn, L.; Sherman, E. J.; Fury, M. G.; Baxi, S. S.; Chandramohan, R.; Dogan, S.; Morris, L. G. T.; Cullen, G. D.; Haque, S.; more...
    Annals of Oncology (2016)

    Fulltext@MSK | Save
  • What hides behind the MASC: Clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC)
    Journal Article

    Drilon, A.; Li, G.; Dogan, S.; Gounder, M.; Shen, R.; Arcila, M.; Wang, L.; Hyman, D. M.; Hechtman, J.; Wei, G.; more...
    Annals of Oncology (2016)

    Fulltext@MSK | Save